menu ☰
menu ˟

Dupilumab shows promise for uncontrolled persistent asthma in phase 3 trial

12 Sep 2017
Results from the phase 3 Liberty Asthma Quest trial demonstrated that the investigational drug, dupilumab, reduced severe exacerbations and improved lung function in patients with uncontrolled persistent asthma, according to a press release issued by...

Click here to view the full article which appeared in Allergy Immunology

IPH Logo